24.65
+1.86%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fagron
Its shares trade on Euronext Brussels under the ticker FAGR.BR. It has been listed since 5 October 2007. In the fiscal year to 31 December 2025, it reported revenue of €952.2m and net income of €91.0m. At that date it held total assets of €1.24bn and shareholders' equity of €551.6m.
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. The company is headquartered in Nazareth, Oost-Vlaanderen. The company went IPO on 2007-10-05. The company operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 5 Oct 2007
- Employees
- 2,728
- Website
- fagron.com ↗
Leadership
Pay as last reported
- Mr. Koen HoffmanIndependent Chairman of the Board - Representing AHOK BV€110,000
- Mr. Rafael PadillaChief Executive Officer, Executive Director, since 2017€2.7m
- Mrs. Karin de JongChief Financial Officer, Executive Director, since 2016€1.5m
- Ms. Vera BakkerChief Operations Officer, since 2022€7,500
- Mr. Kostas KouloridasArea Leader, EMEA
- Mr. Geraldino NederArea Leader, Latin America
- Mr. Andrew PulidoArea Leader, North America
- Mr. Johan VerlindenHead - Legal and M&A
- Mr. Klaus RoehrigNon-Executive Director€54,400
- Mrs. Ann DesenderNon-Executive Independent Director€52,000
- Mr. Neeraj SharmaNon-Executive Independent Director€40,000
- Mr. Robert ten HoedtNon-Executive Independent Director€40,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 64
- Social
- 99
- Governance
- 60
- Direct emissions (scope 1)
- 3,871 t
- Energy emissions (scope 2)
- 9,246 t
- Value chain emissions (scope 3)
- 282,802 t
- Women in the workforce
- 56.5%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fagron NV possesses several key strengths that contribute to its success in the market. Firstly, the company has established a strong reputation as a leader in pharmaceutical compounding, offering customized medication solutions to healthcare providers. This expertise and experience provide Fagron NV with a competitive advantage over its rivals.
- Another strength of Fagron NV lies in its global presence and widespread distribution network. The company operates in various countries, enabling it to reach a diverse range of customers and expand its market share. This international reach helps Fagron NV to mitigate risks associated with regional market fluctuations.
Weaknesses
- Despite its strengths, Fagron NV also faces certain weaknesses that could hinder its growth potential. One such weakness is its reliance on external suppliers for raw materials. Any disruptions in the supply chain could affect the company's ability to fulfill customer orders, potentially leading to customer dissatisfaction and loss of market share.
- Additionally, Fagron NV operates in a highly regulated industry, subject to strict compliance requirements. This can pose challenges in terms of additional costs for regulatory compliance and potential restrictions on product innovation and development. These factors may limit the company's ability to quickly respond to market changes or introduce new product lines.
Opportunities
- Fagron NV has several opportunities it can capitalize on to further enhance its position in the market. One such opportunity lies in the growing demand for personalized medication solutions. As the healthcare industry continues to evolve, there is an increasing focus on individualized treatment options. Fagron NV can leverage its expertise in pharmaceutical compounding to cater to this emerging market segment.
- Another opportunity for Fagron NV lies in expanding its product portfolio to include complementary healthcare products. By diversifying its offerings, the company can tap into new customer segments and revenue streams. This expansion can be achieved through strategic partnerships or acquisitions of established brands in the complementary healthcare sector.
Threats
- Fagron NV is not immune to threats that may impact its business operations. One major threat is the increasing competition in the pharmaceutical compounding industry. The market is witnessing the entry of new players, both domestic and international, who aim to take advantage of the growing demand for personalized medication. Fagron NV must stay vigilant and continuously innovate to maintain its competitive edge.
- Additionally, changes in government regulations and healthcare policies can pose threats to Fagron NV's operations. Alterations in reimbursement policies or drug pricing regulations can impact the company's profitability and pricing strategy. Fagron NV must closely monitor and adapt to any regulatory changes to mitigate potential risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.